| Year |
Citation |
Score |
| 2018 |
Slayden RA, Dawson CC, Cummings JE. Toxin-antitoxin systems and regulatory mechanisms in Mycobacterium tuberculosis. Pathogens and Disease. 76. PMID 29788125 DOI: 10.1093/Femspd/Fty039 |
0.386 |
|
| 2017 |
Cummings JE, Slayden RA. Transient In Vivo Resistance Mechanisms of Burkholderia pseudomallei to Ceftazidime and Molecular Markers for Monitoring Treatment Response. Plos Neglected Tropical Diseases. 11: e0005209. PMID 28081127 DOI: 10.1371/Journal.Pntd.0005209 |
0.323 |
|
| 2016 |
Knudson SE, Cummings JE, Bommineni GR, Pan P, Tonge PJ, Slayden RA. Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 101: 8-14. PMID 27865404 DOI: 10.1016/J.Tube.2016.07.016 |
0.327 |
|
| 2016 |
Wang K, Langevin S, O'Hern CS, Shattuck MD, Ogle S, Forero A, Morrison J, Slayden R, Katze MG, Kirby M. Anomaly Detection in Host Signaling Pathways for the Early Prognosis of Acute Infection. Plos One. 11: e0160919. PMID 27532264 DOI: 10.1371/Journal.Pone.0160919 |
0.303 |
|
| 2016 |
Thanna S, Knudson SE, Grzegorzewicz A, Kapil S, Goins CM, Ronning DR, Jackson M, Slayden RA, Sucheck SJ. Synthesis and evaluation of new 2-aminothiophenes against Mycobacterium tuberculosis. Organic & Biomolecular Chemistry. PMID 27251120 DOI: 10.1039/C6Ob00821F |
0.374 |
|
| 2016 |
Bommineni GR, Kapilashrami K, Cummings JE, Lu Y, Knudson SE, Gu C, Walker SG, Slayden RA, Tonge PJ. Thiolactomycin-based inhibitors of bacterial β-ketoacyl-ACP synthases with in vivo activity. Journal of Medicinal Chemistry. PMID 27187871 DOI: 10.1021/Acs.Jmedchem.6B00236 |
0.344 |
|
| 2015 |
Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA. Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. The Journal of Antimicrobial Chemotherapy. PMID 26245639 DOI: 10.1093/Jac/Dkv226 |
0.359 |
|
| 2014 |
Knudson SE, Kumar K, Awasthi D, Ojima I, Slayden RA. In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis. Tuberculosis (Edinburgh, Scotland). 94: 271-6. PMID 24746463 DOI: 10.1016/J.Tube.2014.03.007 |
0.369 |
|
| 2014 |
Schiebel J, Chang A, Shah S, Lu Y, Liu L, Pan P, Hirschbeck MW, Tareilus M, Eltschkner S, Yu W, Cummings JE, Knudson SE, Bommineni GR, Walker SG, Slayden RA, et al. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor. The Journal of Biological Chemistry. 289: 15987-6005. PMID 24739388 DOI: 10.1074/Jbc.M113.532804 |
0.345 |
|
| 2014 |
Knudson SE, Awasthi D, Kumar K, Carreau A, Goullieux L, Lagrange S, Vermet H, Ojima I, Slayden RA. A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis. Plos One. 9: e93953. PMID 24736743 DOI: 10.1371/Journal.Pone.0093953 |
0.365 |
|
| 2014 |
Park B, Awasthi D, Chowdhury SR, Melief EH, Kumar K, Knudson SE, Slayden RA, Ojima I. Design, synthesis and evaluation of novel 2,5,6-trisubstituted benzimidazoles targeting FtsZ as antitubercular agents. Bioorganic & Medicinal Chemistry. 22: 2602-12. PMID 24726304 DOI: 10.1016/J.Bmc.2014.03.035 |
0.31 |
|
| 2014 |
Pan P, Knudson SE, Bommineni GR, Li HJ, Lai CT, Liu N, Garcia-Diaz M, Simmerling C, Patil SS, Slayden RA, Tonge PJ. Time-dependent diaryl ether inhibitors of InhA: structure-activity relationship studies of enzyme inhibition, antibacterial activity, and in vivo efficacy. Chemmedchem. 9: 776-91. PMID 24616444 DOI: 10.1002/Cmdc.201300429 |
0.359 |
|
| 2014 |
Cummings JE, Beaupre AJ, Knudson SE, Liu N, Yu W, Neckles C, Wang H, Khanna A, Bommineni GR, Trunck LA, Schweizer HP, Tonge PJ, Slayden RA. Substituted diphenyl ethers as a novel chemotherapeutic platform against Burkholderia pseudomallei. Antimicrobial Agents and Chemotherapy. 58: 1646-51. PMID 24379198 DOI: 10.1128/Aac.02296-13 |
0.336 |
|
| 2014 |
Cummings JE, Kingry LC, Rholl DA, Schweizer HP, Tonge PJ, Slayden RA. The Burkholderia pseudomallei enoyl-acyl carrier protein reductase FabI1 is essential for in vivo growth and is the target of a novel chemotherapeutic with efficacy. Antimicrobial Agents and Chemotherapy. 58: 931-5. PMID 24277048 DOI: 10.1128/Aac.00176-13 |
0.688 |
|
| 2013 |
Awasthi D, Kumar K, Knudson SE, Slayden RA, Ojima I. SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents. Journal of Medicinal Chemistry. 56: 9756-70. PMID 24266862 DOI: 10.1021/Jm401468W |
0.33 |
|
| 2013 |
Ramirez MV, Dawson CC, Crew R, England K, Slayden RA. MazF6 toxin of Mycobacterium tuberculosis demonstrates antitoxin specificity and is coupled to regulation of cell growth by a Soj-like protein. Bmc Microbiology. 13: 240. PMID 24172039 DOI: 10.1186/1471-2180-13-240 |
0.316 |
|
| 2013 |
Schenkel AR, Kingry LC, Slayden RA. The ly49 gene family. A brief guide to the nomenclature, genetics, and role in intracellular infection. Frontiers in Immunology. 4: 90. PMID 23596445 DOI: 10.3389/Fimmu.2013.00090 |
0.666 |
|
| 2013 |
Slayden RA, Jackson M, Zucker J, Ramirez MV, Dawson CC, Crew R, Sampson NS, Thomas ST, Jamshidi N, Sisk P, Caspi R, Crick DC, McNeil MR, Pavelka MS, Niederweis M, et al. Updating and curating metabolic pathways of TB. Tuberculosis (Edinburgh, Scotland). 93: 47-59. PMID 23375378 DOI: 10.1016/J.Tube.2012.11.001 |
0.305 |
|
| 2013 |
Kingry LC, Cummings JE, Brookman KW, Bommineni GR, Tonge PJ, Slayden RA. The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection. Journal of Bacteriology. 195: 351-8. PMID 23144254 DOI: 10.1128/Jb.01957-12 |
0.683 |
|
| 2012 |
Yan R, Scott Lynn N, Kingry LC, Yi Z, Erickson T, Slayden RA, Dandy DS, Lear KL. Detection of virus-like nanoparticles via scattering using a chip-scale optical biosensor Applied Physics Letters. 101. DOI: 10.1063/1.4758294 |
0.651 |
|
| 2011 |
Li X, Liu N, Zhang H, Knudson SE, Li HJ, Lai CT, Simmerling C, Slayden RA, Tonge PJ. CoA Adducts of 4-Oxo-4-Phenylbut-2-enoates: Inhibitors of MenB from the M. tuberculosis Menaquinone Biosynthesis Pathway. Acs Medicinal Chemistry Letters. 2: 818-823. PMID 22267981 DOI: 10.1021/Ml200141E |
0.346 |
|
| 2011 |
England K, Crew R, Slayden RA. Mycobacterium tuberculosis septum site determining protein, Ssd encoded by rv3660c, promotes filamentation and elicits an alternative metabolic and dormancy stress response. Bmc Microbiology. 11: 79. PMID 21504606 DOI: 10.1186/1471-2180-11-79 |
0.328 |
|
| 2011 |
Liu N, Cummings JE, England K, Slayden RA, Tonge PJ. Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. The Journal of Antimicrobial Chemotherapy. 66: 564-73. PMID 21393229 DOI: 10.1093/Jac/Dkq509 |
0.317 |
|
| 2011 |
Kumar K, Awasthi D, Lee SY, Zanardi I, Ruzsicska B, Knudson S, Tonge PJ, Slayden RA, Ojima I. Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents. Journal of Medicinal Chemistry. 54: 374-81. PMID 21126020 DOI: 10.1021/Jm1012006 |
0.34 |
|
| 2011 |
Kingry LC, Troyer RM, Marlenee NL, Bielefeldt-Ohmann H, Bowen RA, Schenkel AR, Dow SW, Slayden RA. Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis. Microbes and Infection / Institut Pasteur. 13: 261-75. PMID 21070859 DOI: 10.1016/J.Micinf.2010.10.022 |
0.68 |
|
| 2011 |
Yan R, Lynn NS, Kingry LC, Yi Z, Slayden RA, Dandy DS, Lear KL. Waveguide biosensor with integrated detector array for tuberculosis testing Applied Physics Letters. 98. DOI: 10.1063/1.3520142 |
0.701 |
|
| 2010 |
Kumar K, Awasthi D, Berger WT, Tonge PJ, Slayden RA, Ojima I. Discovery of anti-TB agents that target the cell-division protein FtsZ. Future Medicinal Chemistry. 2: 1305-23. PMID 21339840 DOI: 10.4155/Fmc.10.220 |
0.366 |
|
| 2010 |
Li X, Liu N, Zhang H, Knudson SE, Slayden RA, Tonge PJ. Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry Letters. 20: 6306-9. PMID 20850304 DOI: 10.1016/J.Bmcl.2010.08.076 |
0.361 |
|
| 2010 |
Yan R, Lynn NS, Kingry LC, Slayden RA, Dandy DS, Lear KL. An optical waveguide array biosensor for serology - biomed 2010. Biomedical Sciences Instrumentation. 46: 45-50. PMID 20467070 |
0.673 |
|
| 2010 |
Yan R, Kingry LC, Slayden RA, Lear KL. Immunoassay demonstration using a local evanescent array coupled biosensor Progress in Biomedical Optics and Imaging - Proceedings of Spie. 7559. DOI: 10.1117/12.842201 |
0.692 |
|
| 2010 |
Yan R, Lynn NS, Kingry LC, Slayden RA, Dandy DS, Leara KL. Demonstration of nanoparticle detection using a local evanescent array coupled biosensor 2010 23rd Annual Meeting of the Ieee Photonics Society, Photinics 2010. 214-215. DOI: 10.1109/Photonics.2010.5698835 |
0.675 |
|
| 2010 |
Yan R, Scott Lynn N, Kingry LC, Dandy DS, Slayden RA, Lear KL. Waveguide biosensor with integrated photodetector array for tuberculosis serology Lasers and Electro-Optics/Quantum Electronics and Laser Science Conference: 2010 Laser Science to Photonic Applications, Cleo/Qels 2010. |
0.697 |
|
| 2010 |
Yan R, Scott Lynn N, Kingry LC, Dandy DS, Slayden RA, Lear KL. Waveguide biosensor with integrated photodetector array for tuberculosis serology Lasers and Electro-Optics/Quantum Electronics and Laser Science Conference: 2010 Laser Science to Photonic Applications, Cleo/Qels 2010. |
0.697 |
|
| 2009 |
England K, am Ende C, Lu H, Sullivan TJ, Marlenee NL, Bowen RA, Knudson SE, Knudson DL, Tonge PJ, Slayden RA. Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia. The Journal of Antimicrobial Chemotherapy. 64: 1052-61. PMID 19734171 DOI: 10.1093/Jac/Dkp307 |
0.327 |
|
| 2009 |
Sun D, Scherman MS, Jones V, Hurdle JG, Woolhiser LK, Knudson SE, Lenaerts AJ, Slayden RA, McNeil MR, Lee RE. Discovery, synthesis, and biological evaluation of piperidinol analogs with anti-tuberculosis activity. Bioorganic & Medicinal Chemistry. 17: 3588-94. PMID 19386501 DOI: 10.1016/J.Bmc.2009.04.005 |
0.345 |
|
| 2009 |
Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC, Angala SK, Chatterjee D, Biswas K, Narayanasamy P, Kurosu M, Crick DC. Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Molecular Microbiology. 72: 85-97. PMID 19220750 DOI: 10.1111/J.1365-2958.2009.06625.X |
0.346 |
|
| 2009 |
Lu H, England K, am Ende C, Truglio JJ, Luckner S, Reddy BG, Marlenee NL, Knudson SE, Knudson DL, Bowen RA, Kisker C, Slayden RA, Tonge PJ. Slow-onset inhibition of the FabI enoyl reductase from francisella tularensis: residence time and in vivo activity. Acs Chemical Biology. 4: 221-31. PMID 19206187 DOI: 10.1021/Cb800306Y |
0.344 |
|
| 2009 |
Slayden RA, Belisle JT. Morphological features and signature gene response elicited by inactivation of FtsI in Mycobacterium tuberculosis. The Journal of Antimicrobial Chemotherapy. 63: 451-7. PMID 19109339 DOI: 10.1093/Jac/Dkn507 |
0.34 |
|
| 2009 |
Gonzalez-Juarrero M, Kingry LC, Ordway DJ, Henao-Tamayo M, Harton M, Basaraba RJ, Hanneman WH, Orme IM, Slayden RA. Immune response to Mycobacterium tuberculosis and identification of molecular markers of disease. American Journal of Respiratory Cell and Molecular Biology. 40: 398-409. PMID 18787176 DOI: 10.1165/Rcmb.2008-0248Oc |
0.701 |
|
| 2008 |
Respicio L, Nair PA, Huang Q, Anil B, Tracz S, Truglio JJ, Kisker C, Raleigh DP, Ojima I, Knudson DL, Tonge PJ, Slayden RA. Characterizing septum inhibition in Mycobacterium tuberculosis for novel drug discovery. Tuberculosis (Edinburgh, Scotland). 88: 420-9. PMID 18479968 DOI: 10.1016/J.Tube.2008.03.001 |
0.368 |
|
| 2008 |
am Ende CW, Knudson SE, Liu N, Childs J, Sullivan TJ, Boyne M, Xu H, Gegina Y, Knudson DL, Johnson F, Peloquin CA, Slayden RA, Tonge PJ. Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorganic & Medicinal Chemistry Letters. 18: 3029-33. PMID 18457948 DOI: 10.1016/J.Bmcl.2008.04.038 |
0.311 |
|
| 2007 |
Boyne ME, Sullivan TJ, amEnde CW, Lu H, Gruppo V, Heaslip D, Amin AG, Chatterjee D, Lenaerts A, Tonge PJ, Slayden RA. Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors. Antimicrobial Agents and Chemotherapy. 51: 3562-7. PMID 17664324 DOI: 10.1128/Aac.00383-07 |
0.349 |
|
| 2007 |
Huang Q, Tonge PJ, Slayden RA, Kirikae T, Ojima I. FtsZ: a novel target for tuberculosis drug discovery. Current Topics in Medicinal Chemistry. 7: 527-43. PMID 17346197 DOI: 10.2174/156802607780059790 |
0.354 |
|
| 2007 |
Tonge PJ, Kisker C, Slayden RA. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis. Current Topics in Medicinal Chemistry. 7: 489-98. PMID 17346194 DOI: 10.2174/156802607780059781 |
0.381 |
|
| 2006 |
Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li HJ, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ. High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. Acs Chemical Biology. 1: 43-53. PMID 17163639 DOI: 10.1021/Cb0500042 |
0.37 |
|
| 2006 |
Groathouse NA, Amin A, Marques MA, Spencer JS, Gelber R, Knudson DL, Belisle JT, Brennan PJ, Slayden RA. Use of protein microarrays to define the humoral immune response in leprosy patients and identification of disease-state-specific antigenic profiles. Infection and Immunity. 74: 6458-66. PMID 16966411 DOI: 10.1128/Iai.00041-06 |
0.308 |
|
| 2006 |
Sartain MJ, Slayden RA, Singh KK, Laal S, Belisle JT. Disease state differentiation and identification of tuberculosis biomarkers via native antigen array profiling. Molecular & Cellular Proteomics : McP. 5: 2102-13. PMID 16899542 DOI: 10.1074/Mcp.M600089-Mcp200 |
0.349 |
|
| 2006 |
Slayden RA, Knudson DL, Belisle JT. Identification of cell cycle regulators in Mycobacterium tuberculosis by inhibition of septum formation and global transcriptional analysis. Microbiology (Reading, England). 152: 1789-97. PMID 16735741 DOI: 10.1099/Mic.0.28762-0 |
0.347 |
|
| 2006 |
Huang Q, Kirikae F, Kirikae T, Pepe A, Amin A, Respicio L, Slayden RA, Tonge PJ, Ojima I. Targeting FtsZ for antituberculosis drug discovery: noncytotoxic taxanes as novel antituberculosis agents. Journal of Medicinal Chemistry. 49: 463-6. PMID 16420032 DOI: 10.1021/Jm050920Y |
0.347 |
|
| 2003 |
Phetsuksiri B, Jackson M, Scherman H, McNeil M, Besra GS, Baulard AR, Slayden RA, DeBarber AE, Barry CE, Baird MS, Crick DC, Brennan PJ. Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. The Journal of Biological Chemistry. 278: 53123-30. PMID 14559907 DOI: 10.1074/Jbc.M311209200 |
0.381 |
|
| 2003 |
Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. Journal of Combinatorial Chemistry. 5: 172-87. PMID 12625709 DOI: 10.1021/Cc020071P |
0.308 |
|
| 2002 |
Slayden RA, Barry CE. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in Mycobacterium tuberculosis Tuberculosis. 82: 149-160. PMID 12464486 DOI: 10.1054/Tube.2002.0333 |
0.345 |
|
| 2002 |
Rosenkrands I, Slayden RA, Crawford J, Aagaard C, Barry CE, Andersen P. Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins. Journal of Bacteriology. 184: 3485-91. PMID 12057942 DOI: 10.1128/Jb.184.13.3485-3491.2002 |
0.335 |
|
| 2000 |
Slayden RA, Lee RE, Barry CE. Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis Molecular Microbiology. 38: 514-525. PMID 11069675 DOI: 10.1046/J.1365-2958.2000.02145.X |
0.325 |
|
| 2000 |
Behr MA, Schroeder BG, Brinkman JN, Slayden RA, Barry CE. A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927. Journal of Bacteriology. 182: 3394-9. PMID 10852869 DOI: 10.1128/Jb.182.12.3394-3399.2000 |
0.32 |
|
| 2000 |
Barry CE, Slayden RA, Sampson AE, Lee RE. Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs Biochemical Pharmacology. 59: 221-231. PMID 10609550 DOI: 10.1016/S0006-2952(99)00253-1 |
0.339 |
|
| 1998 |
Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, Crane DD, Musser JM, Barry CE. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science (New York, N.Y.). 280: 1607-10. PMID 9616124 DOI: 10.1126/Science.280.5369.1607 |
0.334 |
|
| 1998 |
Barry CE, Slayden RA, Mdluli K. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis Drug Resistance Updates. 1: 128-134. DOI: 10.1016/S1368-7646(98)80028-9 |
0.314 |
|
| 1996 |
Slayden RA, Lee RE, Armour JW, Cooper AM, Orme IM, Brennan PJ, Besra GS. Antimycobacterial action of thiolactomycin: An inhibitor of fatty acid and mycolic acid synthesis Antimicrobial Agents and Chemotherapy. 40: 2813-2819. PMID 9124847 DOI: 10.1128/Aac.40.12.2813 |
0.346 |
|
| 1995 |
Mikusova K, Slayden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol Antimicrobial Agents and Chemotherapy. 39: 2484-2489. PMID 8585730 DOI: 10.1128/Aac.39.11.2484 |
0.303 |
|
| Show low-probability matches. |